Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
GHRP-6 (Cardiac) (GHRP6C) is a metabolic peptide, at the preclinical stage in the published literature. Beyond GH release, GHRP-6 has demonstrated independent cardioprotective effects in ischemia research.
Beyond GH release, GHRP-6 has demonstrated independent cardioprotective effects in ischemia research.
| Research Status | Preclinical |
|---|---|
| Half-Life | 15-30 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-300 mcg |
CD36 receptor activation in cardiac tissue, independent of GH release.
Beyond GH release, GHRP-6 has demonstrated independent cardioprotective effects in ischemia research.
CD36 receptor activation in cardiac tissue, independent of GH release.
GHRP-6 (Cardiac) is at the following stage in the published literature: Preclinical. All information is for research and educational purposes only.
Reported half-life: 15-30 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.